Sunday, August 30, 2015

NuPathe to test IPO market

The Conshohocken drug developer that's been working on a patch to treat migraine is seeking $86 million.

NuPathe to test IPO market

0 comments

NuPathe Inc., of Conshohocken, hopes to raise $86.3 million in an initial public offering, according to a regulatory filing on Friday.

The preliminary prospectus does not list the number of shares NuPathe intends to issue or any price range.

The specialty pharmaceutical company has been working on Zelrix, a single-use patch to treat migraine. In a filing with the Securities and Exchange Commission, NuPathe said it completed a Phase III clinical trial in July 2009 and expects to submit a new drug application with the Food and Drug Administration in the fourth quarter of this year.

(Here's a link to the filing on the SEC's Web site. It's 121 pages plus financial statements.)

NuPathe, which was started in January 2005, is unprofitable like other drug developers that have yet to reach the market with their first product. NuPathe lost $15.6 million in 2009.

The company has raised several rounds of venture capital, including a Series B preferred stock offering that raised $31.1 million between July 2008 and August 2009. Those investors include Quaker BioVentures, Safeguard Scientifics Inc. and SR One Ltd., all local venture capital firms.

NuPathe CEO Jane H. Hollingsworth has worked in senior management of two other local life-sciences firms. She'd been a co-founder and general counsel of Auxilium Pharmaceuticals Inc. Also, she'd been general counsel at IBAH Inc., a contract research organization. She'd also previously practiced law at the Philadelphia firm of Montgomery, McCracken, Walker & Rhoads.

Underwriters for NuPathe's IPO are listed as Leerink Swann and Lazard Capital Markets.

 

Inquirer Columnist
0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at marmstrong@phillynews.com.

Mike Armstrong Inquirer Columnist
Also on Philly.com:
letter icon Newsletter